Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 455 entries
Sorted by: Best Match Show Resources per page
Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial

interventions

[No authors listed]
GSID: LlSDU_XMULQJ
H Von Hertzen, G Piaggio, A Peregoudov, J Ding… - The Lancet, 2002 - Elsevier

Background A single 10 mg dose of mifepristone, and two 0· 75 mg doses of levonorgestrel 12 h apart, are effective for emergency contraception. Because no studies had compared the …

Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis

interventions

[No authors listed]
GSID: VKi1JwOtM-wJ
AF Glasier, ST Cameron, PM Fine, SJS Logan… - The Lancet, 2010 - Elsevier

Background Emergency contraception can prevent unintended pregnancies, but current methods are only effective if used as soon as possible after sexual intercourse and before …

Controversies in contraception for women with epilepsy.

Annals of Indian Academy of Neurology

Thomas SV.
PMID: 26425002
Ann Indian Acad Neurol. 2015 Jul-Sep;18(3):278-83. doi: 10.4103/0972-2327.162261.

Contraception is an important choice that offers autonomy to women with regard to prevention of unintended pregnancies. There is wide variation in the contraceptive practices between continents, countries, and societies. The medical eligibility for contraception for sexually active women...

Cite
Thomas SV. Controversies in contraception for women with epilepsy. Ann Indian Acad Neurol. 2015;18(3):278-83doi: 10.4103/0972-2327.162261.
Thomas, S. V. (2015). Controversies in contraception for women with epilepsy. Annals of Indian Academy of Neurology, 18(3), 278-83. https://doi.org/10.4103/0972-2327.162261
Thomas, Sanjeev V. "Controversies in contraception for women with epilepsy." Annals of Indian Academy of Neurology vol. 18,3 (2015): 278-83. doi: https://doi.org/10.4103/0972-2327.162261
Thomas SV. Controversies in contraception for women with epilepsy. Ann Indian Acad Neurol. 2015 Jul-Sep;18(3):278-83. doi: 10.4103/0972-2327.162261. PMID: 26425002; PMCID: PMC4564459.
Copy Download .nbib Format: NLM
Understanding benefits and addressing misperceptions and barriers to intrauterine device access among populations in the United States.

Patient preference and adherence

Yoost J.
PMID: 25050062
Patient Prefer Adherence. 2014 Jul 03;8:947-57. doi: 10.2147/PPA.S45710. eCollection 2014.

Three intrauterine devices (IUDs), one copper and two containing the progestin levonorgestrel, are available for use in the United States. IUDs offer higher rates of contraceptive efficacy than nonlong-acting methods, and several studies have demonstrated higher satisfaction rates and...

Cite
Yoost J. Understanding benefits and addressing misperceptions and barriers to intrauterine device access among populations in the United States. Patient Prefer Adherence. 2014;8:947-57doi: 10.2147/PPA.S45710.
Yoost, J. (2014). Understanding benefits and addressing misperceptions and barriers to intrauterine device access among populations in the United States. Patient preference and adherence, 8947-57. https://doi.org/10.2147/PPA.S45710
Yoost, Jennie. "Understanding benefits and addressing misperceptions and barriers to intrauterine device access among populations in the United States." Patient preference and adherence vol. 8 (2014): 947-57. doi: https://doi.org/10.2147/PPA.S45710
Yoost J. Understanding benefits and addressing misperceptions and barriers to intrauterine device access among populations in the United States. Patient Prefer Adherence. 2014 Jul 03;8:947-57. doi: 10.2147/PPA.S45710. eCollection 2014. PMID: 25050062; PMCID: PMC4090129.
Copy Download .nbib Format: NLM
Knowledge of Latin American Obstetricians and Gynecologists regarding Heavy Menstrual Bleeding.

Obstetrics and gynecology international

Bahamondes L, Marin V, Ciarmatori S, Silva-Filho AL, Acuña JM, Makuch MY.
PMID: 27648073
Obstet Gynecol Int. 2016;2016:6870679. doi: 10.1155/2016/6870679. Epub 2016 Aug 25.

Background. Heavy menstrual bleeding (HMB) is a common gynecological complaint affecting quality of life. Objectives. To assess knowledge on diagnosis and treatments of HMB of Latin American (LA) obstetricians and gynecologists (OBGYNs). Methods. A survey was conducted during a...

Cite
Bahamondes L, Marin V, Ciarmatori S, et al. Knowledge of Latin American Obstetricians and Gynecologists regarding Heavy Menstrual Bleeding. Obstet Gynecol Int. 2016;2016:6870679doi: 10.1155/2016/6870679.
Bahamondes, L., Marin, V., Ciarmatori, S., Silva-Filho, A. L., Acuña, J. M., & Makuch, M. Y. (2016). Knowledge of Latin American Obstetricians and Gynecologists regarding Heavy Menstrual Bleeding. Obstetrics and gynecology international, 20166870679. https://doi.org/10.1155/2016/6870679
Bahamondes, Luis, et al. "Knowledge of Latin American Obstetricians and Gynecologists regarding Heavy Menstrual Bleeding." Obstetrics and gynecology international vol. 2016 (2016): 6870679. doi: https://doi.org/10.1155/2016/6870679
Bahamondes L, Marin V, Ciarmatori S, Silva-Filho AL, Acuña JM, Makuch MY. Knowledge of Latin American Obstetricians and Gynecologists regarding Heavy Menstrual Bleeding. Obstet Gynecol Int. 2016;2016:6870679. doi: 10.1155/2016/6870679. Epub 2016 Aug 25. PMID: 27648073; PMCID: PMC5014946.
Copy Download .nbib Format: NLM
Adenomyosis: a systematic review of medical treatment.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology

Pontis A, D'Alterio MN, Pirarba S, de Angelis C, Tinelli R, Angioni S.
PMID: 27379972
Gynecol Endocrinol. 2016 Sep;32(9):696-700. doi: 10.1080/09513590.2016.1197200. Epub 2016 Jul 05.

Adenomyosis is a heterogeneous gynaecologic condition with a range of clinical presentations, the most common being heavy menstrual bleeding and dysmenorrhoea; however, patients can also be asymptomatic. Several studies support the theory that adenomyosis results from invasion of the...

Cite
Pontis A, D'Alterio MN, Pirarba S, et al. Adenomyosis: a systematic review of medical treatment. Gynecol Endocrinol. 2016;32(9):696-700doi: 10.1080/09513590.2016.1197200.
Pontis, A., D'Alterio, M. N., Pirarba, S., de Angelis, C., Tinelli, R., & Angioni, S. (2016). Adenomyosis: a systematic review of medical treatment. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 32(9), 696-700. https://doi.org/10.1080/09513590.2016.1197200
Pontis, A, et al. "Adenomyosis: a systematic review of medical treatment." Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology vol. 32,9 (2016): 696-700. doi: https://doi.org/10.1080/09513590.2016.1197200
Pontis A, D'Alterio MN, Pirarba S, de Angelis C, Tinelli R, Angioni S. Adenomyosis: a systematic review of medical treatment. Gynecol Endocrinol. 2016 Sep;32(9):696-700. doi: 10.1080/09513590.2016.1197200. Epub 2016 Jul 05. PMID: 27379972.
Copy Download .nbib Format: NLM
Risk of intracranial hypertension with intrauterine levonorgestrel: reply.

Therapeutic advances in drug safety

Etminan M.
PMID: 26834961
Ther Adv Drug Saf. 2016 Feb;7(1):25-6. doi: 10.1177/2042098615621264.

No abstract available.

Cite
Etminan M. Risk of intracranial hypertension with intrauterine levonorgestrel: reply. Ther Adv Drug Saf. 2016;7(1):25-6doi: 10.1177/2042098615621264.
Etminan, M. (2016). Risk of intracranial hypertension with intrauterine levonorgestrel: reply. Therapeutic advances in drug safety, 7(1), 25-6. https://doi.org/10.1177/2042098615621264
Etminan, Mahyar. "Risk of intracranial hypertension with intrauterine levonorgestrel: reply." Therapeutic advances in drug safety vol. 7,1 (2016): 25-6. doi: https://doi.org/10.1177/2042098615621264
Etminan M. Risk of intracranial hypertension with intrauterine levonorgestrel: reply. Ther Adv Drug Saf. 2016 Feb;7(1):25-6. doi: 10.1177/2042098615621264. PMID: 26834961; PMCID: PMC4716392.
Copy Download .nbib Format: NLM
Contraceptive Effectiveness of Levonorgestrel Releasing Intrauterine System.

Medical journal, Armed Forces India

Kapur A, Kumar S.
PMID: 27408116
Med J Armed Forces India. 2008 Apr;64(2):140-2. doi: 10.1016/S0377-1237(08)80058-5. Epub 2011 Jul 21.

BACKGROUND: This study evaluated the contraceptive effectiveness of progesterone releasing intrauterine contraceptive devices (IUCD) and compared it with the Copper T device.METHODS: Seventy patients were selected in each group. Menstrual charts were maintained and data recorded at one, three,...

Cite
Kapur A, Kumar S. Contraceptive Effectiveness of Levonorgestrel Releasing Intrauterine System. Med J Armed Forces India. 2011;64(2):140-2doi: 10.1016/S0377-1237(08)80058-5.
Kapur, A., & Kumar, S. (2008). Contraceptive Effectiveness of Levonorgestrel Releasing Intrauterine System. Medical journal, Armed Forces India, 64(2), 140-2. https://doi.org/10.1016/S0377-1237(08)80058-5
Kapur, A, and Kumar, S. "Contraceptive Effectiveness of Levonorgestrel Releasing Intrauterine System." Medical journal, Armed Forces India vol. 64,2 (2008): 140-2. doi: https://doi.org/10.1016/S0377-1237(08)80058-5
Kapur A, Kumar S. Contraceptive Effectiveness of Levonorgestrel Releasing Intrauterine System. Med J Armed Forces India. 2008 Apr;64(2):140-2. doi: 10.1016/S0377-1237(08)80058-5. Epub 2011 Jul 21. PMID: 27408116; PMCID: PMC4921528.
Copy Download .nbib Format: NLM
Effect of drospirenone on proliferation of human benign and cancerous epithelial breast cells.

Hormone molecular biology and clinical investigation

Seeger H, Ruan X, Neubauer H, Mueck AO.
PMID: 25961257
Horm Mol Biol Clin Investig. 2011 May 01;6(2):211-4. doi: 10.1515/HMBCI.2011.008.

BACKGROUND: Proliferation of human breast epithelial cells is regulated by sex hormones. Epidemiological studies indicate that progestogen addition to estrogen therapy can increase breast cancer risk. However, it remains unclear if all progestogens react in a similar manner. Here,...

Cite
Seeger H, Ruan X, Neubauer H, et al. Effect of drospirenone on proliferation of human benign and cancerous epithelial breast cells. Horm Mol Biol Clin Investig. 2011;6(2):211-4doi: 10.1515/HMBCI.2011.008.
Seeger, H., Ruan, X., Neubauer, H., & Mueck, A. O. (2011). Effect of drospirenone on proliferation of human benign and cancerous epithelial breast cells. Hormone molecular biology and clinical investigation, 6(2), 211-4. https://doi.org/10.1515/HMBCI.2011.008
Seeger, Harald, et al. "Effect of drospirenone on proliferation of human benign and cancerous epithelial breast cells." Hormone molecular biology and clinical investigation vol. 6,2 (2011): 211-4. doi: https://doi.org/10.1515/HMBCI.2011.008
Seeger H, Ruan X, Neubauer H, Mueck AO. Effect of drospirenone on proliferation of human benign and cancerous epithelial breast cells. Horm Mol Biol Clin Investig. 2011 May 01;6(2):211-4. doi: 10.1515/HMBCI.2011.008. PMID: 25961257.
Copy Download .nbib Format: NLM
Pharmacokinetics, tolerability and cycle control of three transdermal contraceptive delivery systems containing different doses of ethinylestradiol and levonorgestrel.

Hormone molecular biology and clinical investigation

Stanczyk FZ, Rubin A, Flood L, Foegh M.
PMID: 25961260
Horm Mol Biol Clin Investig. 2011 May 01;6(2):231-40. doi: 10.1515/HMBCI.2011.004.

BACKGROUND: The only available contraceptive patch, Ortho Evra®, delivers a relatively high dose of estrogen.MATERIALS AND METHODS: Three transdermal contraceptive delivery systems (TCDS) containing low doses of ethinylestradiol (EE) and levonorgestrel (LNG) were evaluated in two open-label randomized trials....

Cite
Stanczyk FZ, Rubin A, Flood L, et al. Pharmacokinetics, tolerability and cycle control of three transdermal contraceptive delivery systems containing different doses of ethinylestradiol and levonorgestrel. Horm Mol Biol Clin Investig. 2011;6(2):231-40doi: 10.1515/HMBCI.2011.004.
Stanczyk, F. Z., Rubin, A., Flood, L., & Foegh, M. (2011). Pharmacokinetics, tolerability and cycle control of three transdermal contraceptive delivery systems containing different doses of ethinylestradiol and levonorgestrel. Hormone molecular biology and clinical investigation, 6(2), 231-40. https://doi.org/10.1515/HMBCI.2011.004
Stanczyk, Frank Z, et al. "Pharmacokinetics, tolerability and cycle control of three transdermal contraceptive delivery systems containing different doses of ethinylestradiol and levonorgestrel." Hormone molecular biology and clinical investigation vol. 6,2 (2011): 231-40. doi: https://doi.org/10.1515/HMBCI.2011.004
Stanczyk FZ, Rubin A, Flood L, Foegh M. Pharmacokinetics, tolerability and cycle control of three transdermal contraceptive delivery systems containing different doses of ethinylestradiol and levonorgestrel. Horm Mol Biol Clin Investig. 2011 May 01;6(2):231-40. doi: 10.1515/HMBCI.2011.004. PMID: 25961260.
Copy Download .nbib Format: NLM
Continuation rates of oral hormonal contraceptives in a cohort of first-time users: a population-based registry study, Sweden 2005-2010.

BMJ open

Josefsson A, Wiréhn AB, Lindberg M, Foldemo A, Brynhildsen J.
PMID: 24141970
BMJ Open. 2013 Oct 18;3(10):e003401. doi: 10.1136/bmjopen-2013-003401.

OBJECTIVE: To investigate if continuation rates in first-time users of oral hormonal contraceptives differed between different formulations and to measure if the rates were related to the prescribing categories, that is, physicians and midwives.DESIGN: A longitudinal national population-based registry...

Cite
Josefsson A, Wiréhn AB, Lindberg M, et al. Continuation rates of oral hormonal contraceptives in a cohort of first-time users: a population-based registry study, Sweden 2005-2010. BMJ Open. 2013;3(10):e003401doi: 10.1136/bmjopen-2013-003401.
Josefsson, A., Wiréhn, A. B., Lindberg, M., Foldemo, A., & Brynhildsen, J. (2013). Continuation rates of oral hormonal contraceptives in a cohort of first-time users: a population-based registry study, Sweden 2005-2010. BMJ open, 3(10), e003401. https://doi.org/10.1136/bmjopen-2013-003401
Josefsson, Ann, et al. "Continuation rates of oral hormonal contraceptives in a cohort of first-time users: a population-based registry study, Sweden 2005-2010." BMJ open vol. 3,10 (2013): e003401. doi: https://doi.org/10.1136/bmjopen-2013-003401
Josefsson A, Wiréhn AB, Lindberg M, Foldemo A, Brynhildsen J. Continuation rates of oral hormonal contraceptives in a cohort of first-time users: a population-based registry study, Sweden 2005-2010. BMJ Open. 2013 Oct 18;3(10):e003401. doi: 10.1136/bmjopen-2013-003401. PMID: 24141970; PMCID: PMC3808784.
Copy Download .nbib Format: NLM
Is single-dose levonorgestrel as effective as other emergency contraception regimens?.

The Journal of family practice

Prunuske J, Cochella S, Gunning K.
PMID: 12681080
J Fam Pract. 2003 Apr;52(4):268, 271-2.

No abstract available.

Cite
Prunuske J, Cochella S, Gunning K. Is single-dose levonorgestrel as effective as other emergency contraception regimens?. J Fam Pract. 2003;52(4):268, 271-2
Prunuske, J., Cochella, S., & Gunning, K. (2003). Is single-dose levonorgestrel as effective as other emergency contraception regimens?. The Journal of family practice, 52(4), 268, 271-2.
Prunuske, Jacob, et al. "Is single-dose levonorgestrel as effective as other emergency contraception regimens?." The Journal of family practice vol. 52,4 (2003): 268, 271-2.
Prunuske J, Cochella S, Gunning K. Is single-dose levonorgestrel as effective as other emergency contraception regimens?. J Fam Pract. 2003 Apr;52(4):268, 271-2. PMID: 12681080.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 455 entries